Table 3 Univariate and multivariate analyses in patients treated with allo-HSCT
Variables | EFS | OS | ||
|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
Univariate analyses | ||||
 MiR-25 (high vs low) | 0.886 (0.553–1.473) | 0.641 | 0.625 (0.364–1.073) | 0.088 |
 WBC (< 20 vs ≥ 20 × 109/L) | 1.530 (0.910–2.571) | 0.108 | 0.949 (0.554–1.628) | 0.851 |
 FLT3-ITD (positive vs negative) | 1.873 (1.020–3.437) | 0.043 | 1.998 (1.053–3.788) | 0.034 |
 NPM1 (mutated vs wild) | 0.913 (0.515–1.619) | 0.755 | 0.879 (0.478–1.617) | 0.678 |
 DNMT3A (mutated vs wild) | 1.106 (0.615–1.989) | 0.737 | 1.269 (0.686–2.347) | 0.447 |
 RUNX1 (mutated vs wild) | 1.375 (0.650–2.907) | 0.404 | 2.253 (1.046–4.849) | 0.038 |
 ITDH1 (mutated vs wild) | 0.985 (0.498–1.949) | 0.966 | 0.810 (0.382–1.718) | 0.582 |
 ITDH2 (mutated vs wild) | 0.569 (0.227–1.425) | 0.229 | 0.931 (0.368–2.357) | 0.880 |
Multivariate analyses | ||||
 MiR-25 (high vs low) | 0.788 (0.421–1.476) | 0.457 | 0.510 (0.266–0.978) | 0.043 |
 WBC (< 20 vs ≥ 20 × 109/L) | 1.343 (0.756–2.386) | 0.314 | 0.827 (0.450–1.519) | 0.540 |
 FLT3-ITD (positive vs negative) | 2.222 (1.044–4.729) | 0.038 | 2.201 (0.951–5.096) | 0.065 |
 NPM1 (mutated vs wild) | 0.586 (0.280–1.227) | 0.156 | 0.560 (0.249–1.259) | 0.161 |
 DNMT3A (mutated vs wild) | 1.058 (0.549–2.037) | 0.867 | 1.514 (0.774–2.963) | 0.226 |
 RUNX1 (mutated vs wild) | 1.483 (0.620–3.545) | 0.376 | 2.671 (1.114–6.402) | 0.028 |
 ITDH1 (mutated vs wild) | 1.265 (0.535–2.944) | 0.592 | 0.781 (0.305–1.999) | 0.606 |
 ITDH2 (mutated vs wild) | 0.524 (0.183–1.498) | 0.228 | 0.499 (0.175–1.424) | 0.194 |